Please login to the form below

Not currently logged in
Email:
Password:

Vernalis

This page shows the latest Vernalis news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA exec takes top job at UK biotech Kymab

Merck KGaA exec takes top job at UK biotech Kymab

He was also founder and CEO of Ribotargets, one of the UK’s earliest biotechs, which was acquired by British Biotech and subsequently renamed Vernalis.

Latest news

  • Boston Scientific makes $4.2bn play for UK’s BTG Boston Scientific makes $4.2bn play for UK’s BTG

    The acquisition of BTG follows the buyout of another veteran of the UK biotech scene, Vernalis, which was acquired by Ligand Pharma in August for $33m, Vernalis's chequered history viewed

  • Vernalis accepts £33m takeover offer from Ligand Pharma Vernalis accepts £33m takeover offer from Ligand Pharma

    Biotech buyout brings team of 70 scientists in Cambridge, UK. After mulling over several takeover offers, UK biotech Vernalis has been won over by an overture from California’s Ligand Pharma ... If Ligand’s offer is approved by Vernalis shareholders,

  • FDA knocks-back second Vernalis cough and cold treatment FDA knocks-back second Vernalis cough and cold treatment

    Vernalis’ hopes of bringing either of its cough-cold drugs CCP-07 and CCP-08 to the US market in time for the 2017-2018 winter have been dashed. ... Ian Garland, chief executive officer of Vernalis, said: “Unfortunately, the outstanding items that

  • Juno cleared to restart CAR-T trial after deaths Juno cleared to restart CAR-T trial after deaths

    Vipadenant was originally developed as a Parkinson's disease candidate by UK company Vernalis and licensed to Biogen, but its development was held back by safety concerns and Biogen eventually abandoned

  • Merck & Co drops Parkinson's prospect preladenant Merck & Co drops Parkinson's prospect preladenant

    2011. Meanwhile, Lundbeck was also working in this area with its Lu AA47070, but discontinued this project a couple of years ago, while Vernalis and Biogen Idec dropped their own candidate

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Corporate acquisition. 245††. Vernalis/  Not disclosed. Adenosine receptor antagonist programme, including the lead drug candidate, V81444.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Keeping the romance under wraps. It was announced in February that Vernalis has licensed its proprietary adenosine receptor antagonist programme, including the phase 1/2 lead compound V81444, for use in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics